Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

Some healthcare stocks are better picks than others. And you won't need a fortune to invest in a few of the best. Here are three no-brainer healthcare stocks to buy with $1,000 right now. Where to ...

Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

AbbVie Inc. stands out as one of the top pharma stocks to buy, according to hedge funds. The company exceeded analyst ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...